Bevacizumab: Clinical Trials

2,638 trials of Bevacizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1271 completed, 359 recruiting, 319 unknown, 286 terminated. 1639 Phase 2, 566 Phase 1, 417 Phase 3, 101 Not applicable, 76 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21639Completed 755, Recruiting 219, Unknown 212, Terminated 201, Active not recruiting 91, Not yet recruiting 90, Withdrawn 62, Suspended 7, Enrolling by invitation 2
Phase 1566Completed 264, Recruiting 99, Terminated 67, Active not recruiting 39, Unknown 34, Not yet recruiting 30, Withdrawn 28, Suspended 5
Phase 3417Completed 193, Recruiting 76, Unknown 50, Active not recruiting 40, Terminated 30, Withdrawn 14, Not yet recruiting 13, Enrolling by invitation 1
Not applicable101Completed 44, Unknown 18, Recruiting 13, Terminated 7, Withdrawn 7, Not yet recruiting 6, Active not recruiting 4, Enrolling by invitation 1, Suspended 1
Phase 476Completed 41, Unknown 8, Recruiting 7, Terminated 7, Withdrawn 7, Not yet recruiting 3, Active not recruiting 2, Enrolling by invitation 1
Early Phase 126Completed 9, Withdrawn 4, Active not recruiting 3, Recruiting 3, Terminated 3, Not yet recruiting 2, Unknown 2

Follow Bevacizumab: new trials by email Literature Review of Bevacizumab trials Research Report on Bevacizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer
Phase 2SuspendedHoly Stone Healthcare Co., Ltd1002027-12-012026-09-18
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma
Phase 1Not yet recruitingUniversität Münster302027-10-012026-11-03
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 3Not yet recruitingDaiichi Sankyo6002027-03-312026-11-13
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace
Phase 2Not yet recruitingChang Gung Memorial Hospital902027-02-012026-11-02
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma
Phase 3RecruitingCity of Hope Medical Center1292027-01-042026-11-05
A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer
Bevacizumab, erlotinib - Metastatic Colorectal Cancer, EGFR Amplified Colorectal Cancer
Phase 2Not yet recruitingKorea University Anam Hospital392027-01-042026-11-17
Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
Bevacizumab (intra-arterial) - Chronic Subdural Hematoma
Phase 1Not yet recruitingDheeraj Gandhi182027-01-012026-07-27
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
INCB123667, Bevacizumab, Placebo - Ovarian Cancer
Phase 3Not yet recruitingIncyte Corporation5902026-12-012026-10-02
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NaviFUS System, Lumason, Bevacizumab - GBM
Not applicableNot yet recruitingUniversity of Cincinnati102026-12-012026-06-04
Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma
Bevacizumab - GBM
Phase 1Not yet recruitingUnity Health Toronto62026-12-012026-11-02
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer
Phase 1 / Phase 2Not yet recruitingCytomX Therapeutics3682026-12-012026-10-28
SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
SHR-A2009 + bevacizumab, Sacituzumab Tirumotecan - Non-squamous Non-small Cell Lung Cancer
Phase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.4902026-11-302026-11-12
A Study of BON-C1393 in Adults With Advanced Solid Tumors
BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors
Phase 1Not yet recruitingBeOne Medicines902026-11-232026-11-18
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Phase 2Not yet recruitingNational Cancer Institute (NCI)502026-11-232026-11-18
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Irinotecan, Oxaliplatin, GFH276 - CRC
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.1502026-11-152026-11-06
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
RC148 plus Telisotuzumab adizutecan, Telisotuzumab adizutecan plus Bevacizumab - Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Phase 2Not yet recruitingRemeGen Co., Ltd.4122026-11-012026-10-26
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC)
Phase 2Not yet recruitingSun Yat-sen University2292026-11-012026-10-16
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer
Phase 3Not yet recruitingGenmab6022026-11-012026-10-05
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma
Phase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.6902026-11-012026-10-29

Showing 20 of 2638. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (487)  ·  Carcinoma, Non-Small-Cell Lung (234)  ·  Breast Neoplasms (197)  ·  Ovarian Neoplasms (189)  ·  Glioblastoma (160)  ·  Carcinoma, Hepatocellular (141)  ·  Neoplasms (130)  ·  Rectal Neoplasms (115)  ·  Colonic Neoplasms (112)  ·  Neoplasm Metastasis (109)  ·  Brain Neoplasms (98)  ·  Lung Neoplasms (96)  ·  Fallopian Tube Neoplasms (94)  ·  Carcinoma, Renal Cell (78)  ·  Glioma (70)

Sponsors

National Cancer Institute (NCI) (161)  ·  Hoffmann-La Roche (156)  ·  M.D. Anderson Cancer Center (76)  ·  Genentech, Inc. (54)  ·  Sun Yat-sen University (46)  ·  Fudan University (40)  ·  SCRI Development Innovations, LLC (32)  ·  Memorial Sloan Kettering Cancer Center (31)  ·  Dana-Farber Cancer Institute (28)  ·  Pfizer (23)  ·  Duke University (21)  ·  Massachusetts General Hospital (21)  ·  Alliance for Clinical Trials in Oncology (20)  ·  ImmunityBio, Inc. (18)  ·  AstraZeneca (17)

Countries

United States (1214)  ·  China (520)  ·  France (277)  ·  Spain (249)  ·  Italy (206)  ·  Canada (176)  ·  Germany (176)  ·  South Korea (174)  ·  United Kingdom (152)  ·  Australia (142)  ·  Japan (138)  ·  Taiwan (127)  ·  Belgium (111)  ·  Netherlands (109)  ·  Brazil (91)

Top investigators

Annick Desjardins, MD, FRCPC (7)  ·  Norman Wolmark, MD (7)  ·  Hamid Ahmadieh, MD (6)  ·  John Boockvar, MD (6)  ·  John D. Hainsworth, MD (6)

Results publications

PMID 37185961, PMID 37146227, PMID 32816630, PMID 33067126, PMID 34616010, PMID 17686822, PMID 21941283, PMID 25098701, PMID 32411431, PMID 37260074, PMID 39777725, PMID 41252656, PMID 10628376, PMID 18024865, PMID 18776057, PMID 19064978, PMID 19097774, PMID 19901100, PMID 20573926, PMID 21383283, PMID 21865400, PMID 22204724, PMID 22204725, PMID 23168366, PMID 24138831, PMID 24637997, PMID 25175099, PMID 25218906, PMID 25240821, PMID 25538173, PMID 26884585, PMID 27501767, PMID 27744512, PMID 27986363, PMID 28237539, PMID 29522361, PMID 30059262, PMID 30293873, PMID 30679026, PMID 30957581, PMID 31101691, PMID 31139483, PMID 31268130, PMID 31276981, PMID 31378656, PMID 32164906, PMID 32278676, PMID 32374423, PMID 32427087, PMID 32997907

NIH funding

2023 (29), 2025 (29), 2008 (22), U10CA180868 (21), U10CA027469 (19), 2017 (18), U10CA021115 (17), 2009 (16), 2015 (14), U10CA032102 (14), 2016 (13), 2014 (12), 2018 (12), U10CA031946 (12), U10CA180820 (12)